30 related articles for article (PubMed ID: 21166708)
1. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.
Brunello E; Brunelli M; Bogina G; CaliĆ² A; Manfrin E; Nottegar A; Vergine M; Molino A; Bria E; Massari F; Tortora G; Cingarlini S; Pedron S; Chilosi M; Zamboni G; Miller K; Martignoni G; Bonetti F
J Exp Clin Cancer Res; 2012 Dec; 31(1):103. PubMed ID: 23270564
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
3. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
Aoyama K; Kamio T; Nishikawa T; Kameoka S
Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
[TBL] [Abstract][Full Text] [Related]
4. Human epidermal growth factor receptor 2 testing: where are we?
De P; Smith BR; Leyland-Jones B
J Clin Oncol; 2010 Oct; 28(28):4289-92. PubMed ID: 20697080
[No Abstract] [Full Text] [Related]
5. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
Brunelli M; Manfrin E; Martignoni G; Bersani S; Remo A; Reghellin D; Chilosi M; Bonetti F
Am J Clin Pathol; 2008 Jun; 129(6):907-11. PubMed ID: 18480007
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
7. Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting.
Vergine M; Brunelli M; Martignoni G; Brunello E; Miller K; Pecori S; Bersani S; Chilosi M; Menestrina F; Manfrin E; Bonetti F
Histopathology; 2010 Dec; 57(6):935-40. PubMed ID: 21166708
[No Abstract] [Full Text] [Related]
8. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
Lee JA; Shaheen M; Walke T; Daly M
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).
van de Vijver MJ
Eur J Cancer; 2001 Jan; 37 Suppl 1():S11-7. PubMed ID: 11167086
[TBL] [Abstract][Full Text] [Related]
10. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
11. The use of HER2 testing in the management of breast cancer.
Ravdin P
Semin Oncol; 2000 Oct; 27(5 Suppl 9):33-42. PubMed ID: 11049055
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
Jiang ZF; Shao ZM; Xu BH
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):158-60. PubMed ID: 20403251
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]